for the main comparison.
| Chromium picolinate supplementation for overweight or obese adults | ||||
|
Population: overweight or obese adults Settings: community volunteers and outpatients Intervention: chromium picolinate Comparison: placebo | ||||
| Outcomes | Relative / absolute effect(s) (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments |
| Health‐related quality of life | See comment | See comment | See comment | Not investigated |
|
Adverse events Follow‐up: 8 weeks to 6 months |
2 serious adverse events and study dropouts after 1000 µg chromium picolinate (2/15 participants); 1 serious adverse event after 400 µg chromium picolinate (1/39 participants); 1 serious adverse event (1/18 participants) and 2 study dropouts on placebo (2/58 participants) | 189 (3) |
⊕⊕⊝⊝ lowa | Only 3/9 studies provided information on adverse events |
| Death from any cause | See comment | See comment | See comment | Not investigated |
| Morbidity | See comment | See comment | See comment | Not investigated |
|
Weight loss [kg] Follow‐up: 12 to 16 weeks |
‐1.1 (‐1.7 to ‐0.4) | 392 (6) |
⊕⊕⊝⊝ lowb | All chromium picolinate doses were pooled |
| Socioeconomic effects | See comment | See comment | See comment | Not investigated |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio | ||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||
aDowngraded by two levels owing to high risk of performance and detection bias, and inadequate reporting in most of the included studies
bDowngraded by two levels owing to indirectness and conflicting evidence between different studies of various doses of chromium picolinate and duration of treatment